Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.1847
Abstract: Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective To determine whether adding… read more here.
Keywords: pfs; egfr mutant; trial; erlotinib ... See more keywords
The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4543
Abstract: Epidermal growth factor receptor (EGFR) mutations were frequently found with concomitant genetic alterations in lung adenocarcinoma (LUAD). This study aimed to investigate the profile of concomitant alterations of EGFR‐mutant LUAD ≤3 cm in size and… read more here.
Keywords: lung adenocarcinoma; egfr mutant; molecular characteristics; characteristics resected ... See more keywords
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Cancer"
DOI: 10.1002/ijc.33904
Abstract: Osimertinib, as a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated EGFR‐mutant nonsmall cell lung cancer (NSCLC) in the FLAURA study. However, the… read more here.
Keywords: egfr; untreated egfr; egfr mutant; survival benefit ... See more keywords
Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Biochemical and Biophysical Research Communications"
DOI: 10.1016/j.bbrc.2017.04.102
Abstract: Abstract EGFR-mutant lung adenocarcinomas contain a subpopulation of cells that have undergone epithelial-to-mesenchymal transition and can grow independently of EGFR. To kill these cancer cells, we need a novel therapeutic approach other than EGFR inhibitors.… read more here.
Keywords: lung adenocarcinoma; egfr; egfr mutant; mutant lung ... See more keywords
USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.07.002
Abstract: As a newly discovered deubiquitinating enzyme, ubiquitin-specific protease 22 (USP22) is predictive of therapeutic outcomes in individual cancer patients. However, its clinical effects on malignancy and its roles in conferring resistance to EGFR-TKIs (epidermal growth… read more here.
Keywords: egfr; egfr mutant; resistance egfr; egfr tkis ... See more keywords
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.08.021
Abstract: INTRODUCTION Previous studies suggested that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression-free survival (PFS) than EGFR-TKI alone as first-line setting for patients with EGFR-mutant non-small-cell lung cancer (NSCLC).… read more here.
Keywords: egfr mutant; egfr tkis; tkis plus; patients egfr ... See more keywords
Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of pharmaceutics"
DOI: 10.1016/j.ijpharm.2019.118762
Abstract: Extracellular vesicles (exosomes, EVs) are cell membrane particles (30-200 nm) secreted by virtually all cells. During intercellular communication in the body, secreted EVs play crucial roles by carrying functional biomolecules (e.g., microRNAs and enzymes) into… read more here.
Keywords: gefitinib treatment; egfr mutant; cancer; cell ... See more keywords
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.08.2028
Abstract: Introduction: Histologic transformation from NSCLC to SCLC is a mechanism of resistance in EGFR‐mutant tumors but is also occasionally observed in nonmutated NSCLC. Methods: We performed a multicenter retrospective collection of cases presenting between 2005… read more here.
Keywords: nsclc sclc; mutant group; egfr mutant; transformation ... See more keywords
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.03.010
Abstract: OBJECTIVES Patients with metastatic EGFR-mutant (mEGFRmt) NSCLC have favorable survival when treated with erlotinib. We hypothesized that treatment failure in most patients is limited to initial sites of disease, in which case incorporating local therapy… read more here.
Keywords: egfr mutant; progression; megfrmt nsclc; failure ... See more keywords
Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.12.008
Abstract: OBJECTIVE Dacomitinib is a potent, irreversible and pan-HER tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Currently, evidence of its activity on brain metastasis is lacking. MATERIALS… read more here.
Keywords: egfr mutant; dacomitinib; metastasis; lung cancer ... See more keywords
First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Sign Up to like & getrecommendations! Published in 2021 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-021-00813-y
Abstract: In the ARTEMIS-CTONG1509 multicenter phase 3 study recently published in Cancer Cell, Zhou et al. investigate the combination of the EGFR tyrosine kinase inhibitor (TKI) erlotinib and antiangiogenic bevacizumab in treatment-naive Chinese patients with advanced… read more here.
Keywords: egfr mutant; line anti; vegf plus; anti vegf ... See more keywords